You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Clinical biomarker for early prediction of chemotherapy-induced peripheral neuropathy
SBC: NEWVENTUREIQ LLC Topic: 102Project Summary / Abstract Chemotherapy induced peripheral neuropathy (CIPN) is a major side effect of oxaliplatin, a key drug in 1st line regimens for treating colorectal cancer. Dose-limiting CIPN prevents rt25% of patients from receiving full, maximally effective dose of oxaliplatin. In addition, 10-40% of patients receiving oxaliplatin-based therapy for colorectal cancer with develop chronic C ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Preclinical evaluation of SERCA2 allosteric activators for pancreatic β-cell protection in diabetes.
SBC: NEURODON, LLC Topic: NIDDKThe overall goal of this collaborative project between Neurodon and Indiana University School of Medicine is the development of compounds that will offer disease-modifying treatments for type 1 (T1D) and type 2 diabetes (T2D) mellitus, a sorely unmet need. In this initial STTR project, we will use our expertise in medicinal chemistry, cell biology, and diabetes pathophysiology to functionally test ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
3D force sensing insoles for wearable, AI empowered, high-fidelity gait monitoring
SBC: Axioforce LLC Topic: NIBIBPROJECT SUMMARYLoss of functional mobility associated with aging is the leading cause of dangerous falls and loss of living independence. Approximately 60% of community-residing individuals rt80 years-old have a gait disorder, and abnormal gait patterns are associated with a greater than two-fold increased risk of institutionalization and death in comparison to age-related adults without gait impa ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Developing a clinical diagnostic tool for age-related cochlear synaptopathy.
SBC: GATEWAY BIOTECHNOLOGY, INC. Topic: NIAAge-related hearing loss (ARHL) is the predominant neurodegenerative disease of aging. Recent animal studies have demonstrated that the earliest cochlear pathology due to noise and aging involves a loss of the inner hair cell ribbon synapse. The early consequences of this synaptic loss are not believed to affect hearing sensitivity, but rather, impair speech understanding in background noise. Whil ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Development and Commercialization of a New Molecularly Targeted Imaging Agent for Multiple Myeloma
SBC: Sarya, LLC Topic: 102PROJECT SUMMARY Sarya LLC (Sarya) is a nuclear medicine technology company formed to commercialize radiopharmaceuticals. The goal of this Fast-Track STTR is to develop a new specific imaging agent for diagnosis, staging, and treatment of the hematological cancer, multiple myeloma (MM). MM is the 2nd most common blood cancer with an estimated 32,000 new cases and 13,000 deaths per year. Accurate de ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Novel Therapy for Hyperphosphatemic Familial Tumoral Calcinosis (hfTC) and Generalized Hyperphosphatemia
SBC: FGF Therapeutics INC. Topic: NIAMSAbstract Hyperphosphatemic familial tumoral calcinosis (hfTC) is a disease in which patients cannot produce the bioactive form of the hormone Fibroblast growth factor-23 (FGF23), which is secreted by osteocytes to rid the body of phosphate by acting on the kidney. hfTC is characterized by markedly elevated serum phosphate (Pi) which causes large intramuscular calcifications to develop. The calcifi ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
IND Enabling Non-Clinical Development of E1v1.11, a Morpholino Anti-Sense Oligonucleotide for the treatment of Spinal Muscular Atrophy.
SBC: Shift Pharmaceuticals Holdings, Inc. Topic: 106Abstract: The objective of this project is to perform the required (and previously approved) IND-enabling experimental work for E1v1.11, a novel drug candidate for Spinal Muscular Atrophy (SMA). SMA is an autosomal recessive disorder that is the leading genetic cause of infantile death worldwide, occurring in ~1:10,000 live births. The gene responsible for SMA is called survival motor neuron-1 (SM ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Class II Human Leukocyte Antigen biologics for antibody-mediated graft rejection.
SBC: Antiger Therapeutics Inc. Topic: NIAIDPROJECT SUMMARY/ABSTRACT The mission of Antiger Therapeutics Inc. is to develop novel immunotherapies for transplant recipients to improve long-term graft outcomes and minimize adverse effects. Antibody-mediated rejection (AMR) is a leading cause of graft loss, with over 3000 new cases per year in the United States and estimated market size of $90 million. However, this estimate is likely to under ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
FimH-Targeting Antibody-Recruiting Molecules as Novel Drugs for Preventing Complicated Urinary Tract Infections
SBC: FIMBRION THERAPEUTICS INC Topic: NIAID1 ABSTRACT. Urinary tract infections (UTI) are extremely common world-wide, and can lead to serious2 complications, including renal scarring and urosepsis. Standard-of-care treatments rely on antibiotics: empiric3 treatment for uncomplicated UTI (uUTI), broad-spectrum for complicated UTI (cUTI), and long-term prophylaxis4 for recurrent UTI (rUTI). This constant antibiotic exposure not only disrupt ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Optimization of small molecule SERCA2b activators to inhibit neuron loss in Alzheimer's disease
SBC: NEURODON, LLC Topic: NIAIn this Phase IIB SBIR project for Alzheimer’s disease (AD) drug development, Neurodon LLC proposes to conduct preclinical development and IND-enabling activities on our novel, orally available lead and backup compounds that, in our preceding Phase II project, showed neuroprotection and beneficial effects on learning and memory in a transgenic model of AD. Despite the enormity of AD as a nationa ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health